Firefly Neuroscience (AIFF) said Tuesday its BNA technology platform is able to assess a patient's biological brain age using cognitive data, potentially leading to a "scalable" approach to early screening for Alzheimer's patients.
The US Food and Drug Administration-approved platform used resting electroencephalography, or EEG, and cognitive EEG to assess the biological age of a person's brain, the company said.
Chief Technology Officer Gil Issachar said the technology "is capable of finding a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia."
Shares of the company soared more than 111% in Tuesday's premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.